Abstract 521P
Background
Cisplatin plus irinotecan (PI) regimen is used for patients with extensive disease (ED)-SCLC. Amrubicin is mainly used for relapsed SCLC. HOT1401/NJLCG1401 trial, open-label randomized phase II trials was designed to assess the benefit of maintenance therapy in patients with ED-SCLC who responded induction therapy.
Methods
Eligible patients were aged 20-74 years; had histologically or cytologically confirmed, ED-SCLC. After induction therapy PI (P: 60mg/m2 on day 1, I: 60mg/m2 on days 1, 8, 15, every 4 weeks for 4 cycles), patients who attained CR, PR and SD were randomized to either maintenance irinotecan (I: 60mg/m2 on days 1, 8, every 3 weeks) or amrubicin (A: 35 mg/m2 on days 1-3 every 3 weeks). The primary endpoint is 6-months PFS rate.
Results
A total of 34 patients were enrolled from 2014 to 2017. Twenty patients had disease progression or incomplete of induction chemotherapy, finally 14 (41.1%) patients were randomly assigned to receive irinotecan (n = 7) and amrubicin (n = 7). This study was terminated prematurely because of low patient accrual. Of the evaluable patients (n = 34) the overall objective response rate was 73%, median progression free survival was 5.7 months (95% CI: 3.6 -11.8), and median overall survival was 20.1 months (95% CI: 13.7-NR). Six months PFS rate was 47 % (95%CI: 31.4-63.2). Sub group analysis showed the patients receive maintenance group showed longer PFS and OS than those without (15.8 months and 3.5 months, respectively p < 0.001), (15.4 months and NR months, respectively p = 0.0016). There was no difference in median PFS between the patients treated with irinotecan and those with amrubicin (7.4 months and 21.1 months, respectively p = 0.63). The most common adverse events were neutropenia, anemia during maintenance therapy. Grade 3 or higher hematological toxicity was observed more frequently in amrubicin arm. Treatment related death was not observed in this study.
Conclusions
Maintenance therapy of irinotecan or amrubicin after induction therapy was well tolerated. Some patients might be effective for maintenance therapy.
Clinical trial identification
UMIN 000013882.
Editorial acknowledgement
Legal entity responsible for the study
HOT/NJLCG.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract